Latest News

STAT Plus: Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead

Rise and shine, everyone, another busy day is on the way. We can tell because the short person made another last-minute dash for the local schoolhouse and a parade of vehicles has passed by the placid Pharmalot campus in a hurry. As for us, we are contemplating such frantic paces with a cup of stimulation — peppermint mocha is the choice today. Perhaps this will inspire you to find one of your own. Meanwhile, time to get cracking. Here are a few tidbits to help you on your journey today. Best of luck, and do keep in touch.

Pete Buttigieg has said he wants drug companies to “thrive,” but thriving under a Buttigieg administration will not be business as usual for the pharmaceutical industry, STAT explains. The former mayor of South Bend, Ind., has an expansive platform to lower drug prices that relies on aggressive planks including Medicare negotiation and, if need be, stripping monopolies from companies determined to have priced their drugs abusively.

Continue to STAT Plus to read the full story…

Source link

Related posts

Scientific Symposium at LABVOLUTION focuses on key issues in life sciences


Age Often Dampens Narcissists' Self-Love, Study Finds


Finnish biotech innovation hits billion-euro markets


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World